"10.1371_journal.pone.0114621","plos one","2014-12-04T00:00:00Z","Xiangmei Zhang; Kunihiro Yamaoka; Koshiro Sonomoto; Hiroaki Kaneko; Makoto Satake; Yuka Yamamoto; Masahiro Kondo; Jidong Zhao; Ippei Miyagawa; Kaoru Yamagata; Shunsuke Fukuyo; Yosuke Okada; Yoshiya Tanaka","The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan; Integrative Technology Research Institute, Teijin Limited, Tokyo, Japan; Pharmacology Research Laboratories I, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan","Conceived and designed the experiments: XZ K. Yamaoka KS HK MS YY MK JZ IM K. Yamagata SF YO YT. Performed the experiments: XZ KS MK JZ IM K. Yamagata. Analyzed the data: XZ K. Yamaoka KZ MK JZ IM K. Yamagata YT. Contributed reagents/materials/analysis tools: HK MS YY YT. Contributed to the writing of the manuscript: XZ K. Yamaoka KS YT. Other: We thank Ms. Noda K. and Ms. Adachi T. for the excellent technical assistant.","Hiroaki Kaneko, Makoto Satake and Yuka Yamamoto are employees of the Teijin Limited. Masahiro Kondo is employee of the Mitsubishi Tanabe Pharma Corporation. Dr. Tanaka has received consulting fees, speaking fees, and/or honoraria from Abbvie, Chugai, Astellas, Takeda, Santen, Mitsubishi-Tanabe, Pfizer, Janssen, Eisai, Daiichi-Sankyo, UCB, GlaxoSmithKline, Bristol-Myers and has received research grants from Mitsubishi-Tanabe, Chugai, MSD, Astellas, Novartis. Dr. Yamaoka has received consultant fees and speaking fees from Pfizer, Chugai Pharma, Mitsubishi-Tanabe Pharma, Takeda Industrial Pharma, GlaxoSmithkline, Nippon Shinyaku, Eli lilly, Janssen Pharma, Eisai Pharma, Astellas Pharma, Acterlion Pharmaceuticals. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2014","12","Xiangmei Zhang","XZ",13,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
